At Daiichi Sankyo, we have 1 Purpose: to enrich quality of life using groundbreaking technology. Watch our video on the experts who developed our proprietary ADCs and the challenges they overcame through innovation: https://bit.ly/3BjHMF9
Daiichi Sankyo US
Pharmaceutical Manufacturing
Basking Ridge, NJ 192,604 followers
We create life-changing solutions for patients.
About us
At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8
- Website
-
https://daiichisankyo.us/
External link for Daiichi Sankyo US
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Basking Ridge, NJ
- Type
- Public Company
- Specialties
- Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo group of companies and is focused on the development of oncology therapies and specialty medicines., Oncology, and Specialty Medicine
Locations
-
Primary
211 Mt. Airy Road Basking Ridge
Basking Ridge, NJ 07920, US
Employees at Daiichi Sankyo US
-
Jak (J. C.) DeTemple
Top Talent Executive Recruiter to the Biotech/Pharma Industry Leadership Superstars! Top Talent Sourcing Guru! Talent Acquisition & Retention…
-
Hayes Williams
Global Head of Data Governance at Daiichi Sankyo, Inc.
-
Desmon Swanston
-
Joseph Prikazsky
Pharma/Biotech Financial Professional
Updates
-
When we welcome, respect, and empower more voices, we make a powerful difference for our employees and for the patients we strive to help. To Valerie Kuehner, Benefits Manager, celebrating Hispanic Heritage Month is an opportunity to share her Puerto Rican culture with others and cultivate a deeper appreciation for diversity “I am proud of my Hispanic heritage. Being a Latina in the U.S., I've made it my mission to share my experiences and culture with others. I strongly believe exposing people to other cultures will lead them to appreciate the value of diversity and help build inclusive communities.” At Daiichi Sankyo US, our commitment to inclusion and diversity is something we live each day—it’s essential to how we innovate and serve our patients. 🔗Click for more on how we thrive together: https://lnkd.in/eczSwS_s #DSProud #HispanicHeritageMonth #Inclusion #Belonging
-
As we close out the International Advertising Association World Congress 2024 for the Study of Lung Cancer and the ESMO - European Society for Medical Oncology congresses we reflect on the larger purpose of these meetings – to challenge the status quo by collectively sharing the latest clinical advances in oncology in the pursuit of helping as many people as possible impacted by cancer. It was a privilege to share more than 25 abstracts at #WCLC24 and #ESMO24. The full breadth of our data reaffirms our commitment to creating better futures through medicine for patients with cancer and emphasizes the comprehensive scope of our ADC portfolio spanning multiple cancer types. #WCLC24 #ESMO24 #OncologyResearch
-
Making the broadest possible impact on patients’ lives—that's what drives Dalila Sellami, M.D., Vice President, Global Team Leader, Oncology Research & Development, at Daiichi Sankyo US. 🗺 Her remarkable journey traverses three continents and grows from being the first female radiation oncologist in her native Tunisia to leading the global team behind our promising oncology pipeline. 🔗 Read on: https://bit.ly/4dDcQxZ #DSProud #WPSD2024 #PatientSafety
-
#BreakingNews: Today Daiichi Sankyo US and Merck announced topline results from the HERTHENA-Lung02 phase 3 trial for certain patients with locally advanced or metastatic EGFR-mutated #NSCLC (non-small cell lung cancer). Click the image for more information on these top line results.
-
👋 Save the date - #SCDM24 is two weeks away! We’ll be in Boston for the Society for Clinical Data Management (SCDM) Annual Conference from September 29 – October 2. Come meet us at booth # 712 to learn about the team and opportunities for clinical data management. #Hiring #Recruiting
This content isn’t available here
Access this content and more in the LinkedIn app
-
Not at #ESMO24? You can still register to hear Daiichi Sankyo US CEO and Global Head of Oncology Business, Ken Keller speak with Endpoints News Kyle LaHucik one on one followed by the panel discussion “The Next Frontier of ADCs & Beyond”. Tune in on Tuesday, September 17th as Ken discusses breaking news from #ESMO24 and what’s next for ADCs. Click the image to register today. https://bit.ly/4eiZir9
Endpoints at #ESMO24
events.endpts.com
-
#BreakingNews: During the ESMO - European Society for Medical Oncology Society for Medical Oncology congress Daiichi Sankyo US presented first ever data from our second ADC platform from a phase 1 trial of a CLDN6 directed PBD ADC in certain patients with advanced solid tumors known to express CLDN6. Click the image to learn more about these preliminary results.
Press Releases - Daiichi Sankyo US
daiichisankyo.us
-
#BreakingNews: Results of the DESTINY-Breast12 phase 3 trial evaluating our HER2 directed ADC in certain patients with HER2 positive advanced or metastatic breast cancer with or without brain metastases were presented at ESMO - European Society for Medical Oncology Society for Medical Oncology 2024 during a late-breaking oral presentation in #breastcancer. These results as well as others shared throughout #ESMO24 show our continued innovation in breast cancer research. Click the image to learn more about these results and follow Daiichi Sankyo US for more #ESMO24 news.
Press Releases - Daiichi Sankyo US
daiichisankyo.us
-
Interested in biostatistics? Meet us in Maryland at the American Statistical Association - ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop to learn about the team and opportunities to innovate together. #hiring #recruiting
This content isn’t available here
Access this content and more in the LinkedIn app